Crescent Kashmir

Covid-19 vaccine tracker, August 2: Clinical trials of Russian vaccine over

Decrease Font Size Increase Font Size Text Size Print This Page

A potential novel Coronavirus vaccine being developed by Moscow’s Gamaleya Institute had completed clinical trials, and ‘paperwork’ for its ‘registration’ with the country’s regulatory body was underway, Russian media reported on Saturday.

Russia’s health minister was quoted in the news reports as saying that a mass vaccination programme, presumably using this vaccine, would be launched in Russia in October and that doctors and teachers would be among the first groups to be vaccinated.

The reports did not specify whether all the three stages of clinical trials were over, or only stage-II was completed. A news report by Russia’s Tass news agency in the second week of July had said that this candidate vaccine had entered phase-II of clinical trials on July 13. Phase-II trials, in which the vaccine is tested for its ability to trigger immune response in human beings, usually takes a few months to be completed.

But because of the prevailing Covid19 emergency, vaccine developments across the globe are being fast-tracked. Yet, the Russian vaccine has raised concerns because of the speed at which it is being pushed through. It is most likely to be approved without phase-III trials being carried out. Phase-III trials assess whether the vaccine works in real life situations, essentially whether it offers protection to the people against the disease for which it is being developed. Phase-III trials are usually carried out on several thousand volunteers, and takes months or years to be completed.

Some earlier news reports from Russia had indicated that phase-III trials would be carried out alongside the deployment of the vaccine for public use. But there was no mention of this fact on Saturday.

Serum institute of india, oxford covid 19 vaccine, covid-19 vaccine updates, covid-19 vaccine india trials, covid-19 vaccine india news, Serum institute of india Pune, indian express, Blood samples taken from a volunteer during a vaccine trial at Churchill Hospital in Oxford. (Andrew Testa/The New York Times)

The completion of trials are no guarantee of a vaccine getting the approval of the regulator to be used on public. Data generated by human trials are assessed in detail, and in most cases, fail to convince the regulator. Vaccines have a very poor rate of getting approved by regulatory authorities. Only a very small number of vaccines that are developed actually get the approval to be used. In the case of the Russian Coronavirus vaccine, however, a regulatory approval is being taken almost for granted.

Because of these reasons, there is some amount of scepticism with regard to the Russian vaccine. This scepticism was expressed by top US infectious disease expert Anthony Fauci as well, during his testimony to a panel of US lawmakers on Friday.

“I do hope that the Chinese and the Russians are actually testing the vaccines before they are administering the vaccine to anyone. Because claims of having a vaccine ready to distribute before you do testing is problematic at the very least,” Fauci said.

In Chinaone Coronavirus vaccine has already been approved for limited use after completion of phase-II trials. This is being administered only to military personnel for the time being. At least seven Chinese candidates are currently being tested on human beings.

indian express

Leave a Reply

Your email address will not be published. Required fields are marked *